Drug Profile
Research programme: inflammation therapy - Celgene
Alternative Names: CC-16057Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 23 May 2007 Preclinical trials in Inflammation in USA (unspecified route)